


Univ.-Prof. Dr. med. Lars Zender

Division of Translational Gastrointestinal Oncology
Department of Internal Medicine I
University Hospital Tübingen
Otfried-Müller-Str. 10
72076 Tübingen

Phone: +49(0)7071-2984113

Fax: +49(0)7071-292095



EDUCATION AND ACADEMIC POSITIONS

- 1995-2002 Medical School, Medical School Hannover, Hannover, Germany.
- 2002 Medical Approbation (M.D.) by the State of Lower Saxony, Germany.
- 2002 Doctor of Medicine (Dr. med), Grade: “Summa cum laude” (Excellent).
- 2002-2004 Resident and physician scientist in Internal Medicine/Gastroenterology/GI-Oncology, Medical School Hannover, Hannover, Germany.
- 2004-2005 Postdoctoral Fellow (Emmy Noether Phase I stipend of the German Research Foundation), Laboratory of Dr. Scott W. Lowe, Cold Spring Harbor Laboratory, Cold Spring Harbor, USA.
- 2005-2007 Clinical Fellow, Laboratory of Dr. Scott W. Lowe, Cold Spring Harbor Laboratory, Cold Spring Harbor, USA.
- 2008-2012 Group leader (Emmy Noether Research Group and Helmholtz University Research Group) at the Helmholtz Centre for Infection Research and Medical School Hannover.
- 2008-2012 Project Leader “Liver Regeneration” within the Rebirth Cluster of Excellence for Regenerative Sciences, Medical School Hannover.
- 2008-2012 Fellow in Gastroenterology, Hepatology & Endocrinology, Hannover Medical School, Hannover, Germany.
- 2009 Assistant Professor (W1) for Experimental Gastrointestinal Oncology at Medical School Hannover.
- 2010-present Project Leader within the Transregional Collaborative Research Center SFB/TRR77 “Liver Cancer-From Molecular Pathogenesis to Targeted Therapy”, University of Heidelberg and Medical School Hannover.
- 2010-present Partner and Project leader within the EU/FP7 network “HEPTROMIC- Genomic predictors and oncogenic drivers in hepatocellular carcinoma” .
- 2010-present Adjunct Assistant Professor, Cold Spring Harbor Laboratory, Cold Spring Harbor, USA.
- 2012-present Full professor (W3) and Head of the Division of Translational Gastrointestinal Oncology, Department of Internal Medicine I, University Hospital Tübingen.
- 2012-present Member of the scientific advisory board of the Fritz Lipman institute for age research in Jena.
- 2012-present Project Leader within the Collaborative Research Center (SFB) 685 “Immunotherapy”.
- 2013-present Executive board member and Scientific Director of the Comprehensive Cancer Center Tübingen (Südwestdeutsches Tumorzentrum).
- 2013-present Member of the foundation council of the Ludwig Hiermeier Stiftung for applied Cancer Research.
- 2013-present Group leader “Translational Gastrointestinal Oncology Group”, German Cancer Research Center (DKFZ), Heidelberg.

2013-present Head of the Outpatient Clinic for Gastrointestinal Oncology within the Comprehensive Cancer Center Tübingen and Department of Internal Medicine I (Director: Prof. N.P. Malek).

AWARDS AND APPOINTMENTS

2007 Rising Star in European Hepato-Gastroenterology of ASNEMGE (Association of European and Mediterranean Societies of Gastroenterology).
2007 Bear Necessities Pediatric Cancer Foundation Research Award.
2009 GASL Award (German Association for the Study of the Liver), donated by the YAEL Foundation.
2009 Cancer Award of the “Berlin-Brandenburgische Akademie der Wissenschaften” (donated by the Monika Kutzner Foundation).
2009 Award for Research Cooperation and Highest Excellence in Science (ARCHES), donated by the Minerva Foundation and the German Federal Ministry of Education and Research.
2010 Nomination for full Professorship (W3/chair) at Ulm University, Germany (not accepted)
2011 Nomination as faculty member at Cold Spring Harbor Laboratory (not accepted)
2011 Nomination for full Professorship (W3/chair) for Toxicology and Molecular Oncology at Würzburg University (not accepted)
2012 Johann-Georg-Zimmermann Forschungspreis 2011/2012
2012 Carcinogenesis Young Investigator Award 2012 (awarded during EACR 2012)
2013 Deutscher Krebspreis (Category: Experimental Cancer Research)
2014 Gottfried-Wilhelm-Leibnitz Preis of the German Research Foundation.

MEMBERSHIP

- International Liver Cancer Association (ILCA)
- American Association for Cancer Research (AACR)
- German Association for the Study of the Liver (GASL)
- Deutscher Hochschulverband
- Editorial Board Carcinogenesis
- Editorial Board Embo Molecular Medicine

REVIEWER FOR SCIENTIFIC JOURNALS

Nature, Cell, Nature Medicine, Journal of Experimental Medicine, Genes & Development, Oncogene, Hepatology, Journal of Hepatology, Journal Molecular Biology, Cancer Biology and Therapy...

REVIEWER FOR FUNDING AGENCIES

Deutsche Forschungsgemeinschaft (DFG), Deutsche Krebshilfe, Association for International Cancer Research (AICR), Wellcome Trust, Research Foundation Flanders, Dutch Cancer Aid.

SHORT LIST OF FIVE SELECTED PUBLICATIONS

Rudalska R, Dauch D, Longerich T, McJunkin K, Wuestefeld T, Kang TW, Hohmeyer A, Pesic M, Leibold J, von Thun A, Schirmacher P, Zuber J, Weiss KH, Powers S, Malek NP, Eilers M, Sipos B, Lowe SW, Geffers R, Laufer S, **Zender L**. In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer, **Nature medicine**, in press.

Wuestefeld T, Pesic M, Rudalska R, Dauch D, Longerich T, Kang TW, Yevsa T, Heinzmann F, Hoenicke L, Hohmeyer A, Potapova A, Rittelmeyer I, Jarek M, Geffers R, Scharfe M, Klawonn F, Schirmacher P, Malek NP, Ott M, Nordheim A, Vogel A, Manns MP, **Zender L**. A direct in vivo RNAi screen identifies MKK4 as a key regulator of liver regeneration. **Cell**, 2013, 11;153(2):389-401

Liu L, Ulbrich J, Müller J, Wüstefeld T, Aeberhard L, Kress TR, Muthalagu N, Rycak L, Rudalska R, Moll R, Kempa S, **Zender L**, Eilers M, Murphy DJ (2013) Deregulated MYC expression induces dependence upon AMPK-related kinase 5. **Nature** 28;483(7391):608-12.

Kang TW, Yevsa T, Woller N, Hoenicke L, Wuestefeld T, Dauch D, Hohmeyer A, Gereke M, Rudalska R, Potapova A, Iken M, Vucur M, Weiss S, Heikenwälder M, Khan S, Gil J, Bruder D, Manns MP, Schirmacher P, Tacke F, Ott M, Luedde T, Longerich T, Kubicka S, **Zender, L**. “Senescence surveillance” of premalignant hepatocytes limits carcinoma development through an adaptive immune response. **Nature**. 2011 Nov 9;479(7374):547-51.

Zender L, Xue W, Zuber J, Semighini CP, Krasnitz A, Ma B, Zender P, Kubicka S, Luk JM, Schirmacher P, Richard McCombie W, Wigler M, Hicks J, Hannon GJ, Powers S, Lowe SW. An Oncogenomics-Based In Vivo RNAi Screen Identifies Tumor Suppressors in Liver Cancer. **Cell**. 2008 Nov 28;135(5):852-64. Epub 2008 Nov 13.

List of Publications (85 PubMed listed publications, 08/2014)

Original papers:

Rudalska R, Dauch D, Longerich T, McJunkin K, Wuestefeld T, Kang TW, Hohmeyer A, Pesic M, Leibold J, von Thun A, Schirmacher P, Zuber J, Weiss KH, Powers S, Malek NP, Eilers M, Sipos B, Lowe SW, Geffers R, Laufer S, **Zender L**. In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer, **Nature medicine**, in press.

Tschaharganeh DF, Xue W, Calvisi DF, Evert M, Michurina TV, Dow LE, Banito A, Katz SF, Kasthuber ER, Weissmueller S, Huang CH, Lechel A, Andersen JB, Capper D, **Zender L**, Longerich T, Enikolopov G, Lowe SW. p53-Dependent Nestin Regulation Links Tumor Suppression to Cellular Plasticity in Liver Cancer. **Cell**. 2014 Jul 31;158(3):579-92. doi: 10.1016/j.cell.2014.05.051. PubMed PMID: 25083869.

Walz S, Lorenzin F, Morton J, Wiese KE, von Eyss B, Herold S, Rycak L, Dumay-Odelot H, Karim S, Bartkuhn M, Roels F, Wüstefeld T, Fischer M, Teichmann M, **Zender L**, Wei CL, Sansom O, Wolf E, Eilers M. Activation and repression by oncogenic MYC shape tumour-specific gene expression profiles. **Nature**. 2014 Jul 24;511(7510):483-7. doi: 10.1038/nature13473. Epub 2014 Jul 9. PubMed PMID: 25043018.

Winkler J, Ori A, Holzer K, Sticht C, Dauch D, Eiteneuer EM, Pinna F, Geffers R, Ehemann V, Andres-Pons A, Breuhahn K, Longerich T, Bermejo JL, Gretz N, **Zender L**, Schirmacher P, Beck M, Singer S. Prosurvival function of the cellular apoptosis susceptibility/importin- α 1 transport cycle is repressed by p53 in liver cancer. **Hepatology**. 2014 Sep;60(3):884-95. doi: 10.1002/hep.27207. Epub 2014 Jul 17. PubMed PMID: 24799195.

Shilo A, Ben Hur V, Denichenko P, Stein I, Pikarsky E, Rauch J, Kolch W, **Zender L**, Karni R. Splicing factor hnRNP A2 activates the Ras-MAPK-ERK pathway by controlling A-Raf splicing in hepatocellular carcinoma development. **RNA**. 2014 Apr;20(4):505-15. doi: 10.1261/rna.042259.113. Epub 2014 Feb 26. PubMed PMID: 24572810; PubMed Central PMCID: PMC3964912.

Jedicke N, Struever N, Aggrawal N, Welte T, Manns MP, Malek NP, **Zender L**, Janciauskiene S, Wuestefeld T. α -1-antitrypsin inhibits acute liver failure in mice. **Hepatology**. 2014 Jun;59(6):2299-308. doi: 10.1002/hep.27024. Epub 2014 Apr 28. PubMed PMID: 24449466.

Brinkhoff B, Ostroumov D, Heemcke J, Woller N, Gürlevik E, Manns MP, Longerich T, **Zender L**, Harty JT, Kubicka S, Kühnel F, Wirth TC. Microsphere priming facilitates induction of potent therapeutic T-cell immune responses against autochthonous liver cancers. **Eur J Immunol**. 2014 Apr;44(4):1213-24. doi: 10.1002/eji.201343794. Epub 2014 Jan 16. PubMed PMID: 24338782.

Pellegrino R, Calvisi DF, Neumann O, Kolluru V, Wesely J, Chen X, Wang C, Wuestefeld T, Ladu S, Elgohary N, Bermejo JL, Radlwimmer B, Zörnig M, **Zender L**, Dombrowski F, Evert M, Schirmacher P, Longerich T. EEF1A2 inactivates p53 by way of PI3K/AKT/mTOR-dependent stabilization of MDM4 in hepatocellular carcinoma. **Hepatology**. 2014 May;59(5):1886-99. doi: 10.1002/hep.26954. Epub 2014 Mar 27. PubMed PMID: 24285179; PubMed Central PMCID: PMC4115286.

Shimoni-Sebag A, Lebenthal-Loinger I, **Zender L**, Karni R. RRM1 domain of the splicing oncoprotein SRSF1 is required for MEK1-MAPK-ERK activation and cellular transformation. **Carcinogenesis**. 2013 Aug 8. [Epub ahead of print] PubMed PMID: 23843040.

Kapanadze T, Gamrekelashvili J, Ma C, Chan C, Zhao F, Hewitt S, **Zender L**, Kapoor V, Felsher DW, Manns MP, Korangy F, Greten TF. Regulation of accumulation and function of myeloid derived suppressor cells in different murine models of hepatocellular carcinoma. **J Hepatol**. 2013 Jun 22. doi:pii: S0168-8278(13)00421-2. 10.1016/j.jhep.2013.06.010. [Epub ahead of print] PubMed PMID: 23796475.

Acosta JC, Banito A, Wuestefeld T, Georgilis A, Janich P, Morton JP, Athineos D, Kang TW, Lasitschka F, Andrulis M, Pascual G, Morris KJ, Khan S, Jin H, Dharmalingam G, Snijders AP, Carroll T, Capper D, Pritchard C, Inman GJ, Longerich T, Sansom OJ, Benitah SA, **Zender L**, Gil J. A complex secretory program orchestrated by the inflammasome controls paracrine senescence. **Nat Cell Biol**. 2013 Aug;15(8):978-90. doi: 10.1038/ncb2784. Epub 2013 Jun 16. PubMed PMID: 23770676; PubMed Central PMCID: PMC3732483.

Zender S, Nিকেleit I, Wuestefeld T, Sørensen I, Dauch D, Bozko P, El-Khatib M, Geffers R, Bektas H, Manns MP, Gossler A, Wilkens L, Plentz R, **Zender L**, Malek NP. A critical role for notch signaling in the formation of cholangiocellular carcinomas. **Cancer Cell**. 2013 Jun

10;23(6):784-95. doi: 10.1016/j.ccr.2013.04.019. Epub 2013 May 30. PubMed PMID: 23727022.

Zucman-Rossi J, Nault JC, **Zender L**. Primary liver carcinomas can originate from different cell types: a new level of complexity in hepatocarcinogenesis. **Gastroenterology**. 2013 Jul;145(1):53-5. doi: 10.1053/j.gastro.2013.05.024. Epub 2013 May 29. PubMed PMID: 23726876.

Gürlevik E, Fleischmann-Mundt B, Armbrecht N, Longerich T, Woller N, Kloos A, Hoffmann D, Schambach A, Wirth TC, Manns MP, **Zender L**, Kubicka S, Kühnel F. Adjuvant gemcitabine therapy improves survival in a locally induced, R0-resectable model of metastatic intrahepatic cholangiocarcinoma. **Hepatology**. 2013 Sep;58(3):1031-41. doi: 10.1002/hep.26468. Epub 2013 Jul 29. PubMed PMID: 23686746.

Wuestefeld T, Pesic M, Rudalska R, Dauch D, Longerich T, Kang TW, Yevsa T, Heinzmann F, Hoenicke L, Hohmeyer A, Potapova A, Rittelmeyer I, Jarek M, Geffers R, Scharfe M, Klawonn F, Schirmacher P, Malek NP, Ott M, Nordheim A, Vogel A, Manns MP, **Zender L**. A Direct in vivo RNAi screen identifies MKK4 as a key regulator of liver regeneration. **Cell**. 2013 Apr 11;153(2):389-401. doi: 10.1016/j.cell.2013.03.026. PubMed PMID: 23582328.

Braumüller H, Wieder T, Brenner E, Aßmann S, Hahn M, Alkhaled M, Schilbach K, Essmann F, Kneilling M, Griessinger C, Ranta F, Ullrich S, Mocikat R, Braungart K, Mehra T, Fehrenbacher B, Berdel J, Niessner H, Meier F, van den Broek M, Häring HU, Handgretinger R, Quintanilla-Martinez L, Fend F, Pesic M, Bauer J, **Zender L**, Schaller M, Schulze-Osthoff K, Röcken M. T-helper-1-cell cytokines drive cancer into senescence. **Nature**. 2013 Feb 21;494(7437):361-5. doi: 10.1038/nature11824. Epub 2013 Feb 3. PubMed PMID: 23376950.

Schäfer M, Lkhagvasuren O, Klein HU, Elling C, Wüstefeld T, Müller-Tidow C, **Zender L**, Koschmieder S, Dugas M, Ickstadt K. Integrative analyses for omics data: a Bayesian mixture model to assess the concordance of ChIP-chip and ChIP-seq measurements. **J Toxicol Environ Health A**. 2012;75(8-10):461-70. doi: 10.1080/15287394.2012.674914. PubMed PMID: 22686305.

Xue W, Kitzing T, Roessler S, Zuber J, Krasnitz A, Schultz N, Revill K, Weissmueller S, Rappaport AR, Simon J, Zhang J, Luo W, Hicks J, **Zender L**, Wang XW, Powers S, Wigler M, Lowe SW. A cluster of cooperating tumor-suppressor gene candidates in chromosomal deletions. **Proc Natl Acad Sci U S A**. 2012 May 22;109(21):8212-7.

Liu L, Ulbrich J, Müller J, Wüstefeld T, Aeberhard L, Kress TR, Muthalagu N, Rycak L, Rudalska R, Moll R, Kempa S, **Zender L**, Eilers M, Murphy DJ. Deregulated MYC expression induces dependence upon AMPK-related kinase 5. 1. **Nature**. 2012 Mar 28;483(7391):608-12. doi: 10.1038/nature10927.

Wang J, Sun Q, Morita Y, Jiang H, Groß A, Lechel A, Hildner K, Guachalla LM, Gompf A, Hartmann D, Schambach A, Wüstefeld T, Schrezenmeier H, Hofmann WK, Ju Z, Kestler HA, **Zender L**, K. Rudolph KL. Batf defines a differentiation checkpoint limiting hematopoietic stem cell self-renewal in response to DNA damage **Cell**, 2012 Mar 2;148(5):1001-14.

Schulz R, Marchenko ND, Holembowski L, Fingerle-Rowson G, Pesic M, **Zender L**, Döbelstein M, Moll UM. Inhibiting the HSP90 chaperone destabilizes macrophage

migration inhibitory factor and thereby inhibits breast tumor progression. **J Exp Med**. 2012 Feb 13;209(2):275-89. Epub 2012 Jan 23. PubMed PMID: 22271573; PubMed Central PMCID: PMC3280870.

Schneider C, Teufel A, Yevsa T, Staib F, Hohmeyer A, Walenda G, Zimmermann HW, Vucur M, Huss S, Gassler N, Wasmuth HE, Lira SA, **Zender L**, Luedde T, Trautwein C, Tacke F. Adaptive immunity suppresses formation and progression of diethylnitrosamine-induced liver cancer. **Gut**. 2012 Jan 20. [Epub ahead of print] PubMed PMID: 22267597.

Kang TW, Yevsa T, Woller N, Hoenicke L, Wuestefeld T, Dauch D, Hohmeyer A, Gereke M, Rudalska R, Potapova A, Iken M, Vucur M, Weiss S, Heikenwälder M, Khan S, Gil J, Bruder D, Manns MP, Schirmacher P, Tacke F, Ott M, Luedde T, Longerich T, Kubicka S, **Zender L**. "Senescence surveillance" of premalignant hepatocytes limits carcinoma development through an adaptive immune response. **Nature**. 2011 Nov 9;479(7374):547-51.

Sirma H, Kumar M, Meena JK, Witt B, Weise JM, Lechel A, Ande S, Sakk V, Guguen-Guillouzo C, **Zender L**, Rudolph KL, Günes C. The Promoter of Human Telomerase Reverse Transcriptase is Activated during Liver Regeneration and Hepatocyte Proliferation. **Gastroenterology**. 2011 Mar 26. [Epub ahead of print] PubMed PMID: 21447332.

Sawey ET, Chanrion M, Cai C, Wu G, Zhang J, **Zender L**, Zhao A, Busuttill RW, Yee H, Stein L, French DM, Finn RS, Lowe SW, Powers S. Identification of a Therapeutic Strategy Targeting Amplified FGF19 in Liver Cancer by Oncogenomic Screening. **Cancer Cell**. 2011 Mar 8;19(3):347-58. PubMed PMID: 21397858; PubMed Central PMCID: PMC3061399.

Pischke S, Karsten W, Hadem J, Schmidt S, Heiringhoff Heinz K, Helfritz F, Strassburg CP, Lobers J, **Zender L**, Tutarel O, Wedemeyer J, Manns MP, Wedemeyer H, Rifai K, Gebel M. Liver transplantation: A new risk factor for intestinal intussusceptions. **Ann Hepatol**. 2011 Jan 3;10(1):38-42. PubMed PMID: 21301008.

Xu MZ, Chan SW, Liu AM, Wong KF, Fan ST, Chen J, Poon RT, **Zender L**, Lowe SW, Hong W, Luk JM. AXL receptor kinase is a mediator of YAP-dependent oncogenic functions in hepatocellular carcinoma. **Oncogene**. 2011 Mar 10;30(10):1229-40. Epub 2010 Nov 15. PubMed PMID: 21076472.

Gürlevik E, Woller N, Strüver N, Schache P, Kloos A, Manns MP, **Zender L**, Kühnel F, Kubicka S. Selectivity of Oncolytic Viral Replication Prevents Antiviral Immune Response and Toxicity, but Does Not Improve Antitumoral Immunity. **Mol Ther**. 2010 Aug 10.

Kühnel F, Gürlevik E, Wirth TC, Strüver N, Malek NP, Müller-Schilling M, Manns MP, Carnero A, **Zender L**, Kubicka S. Targeting of p53-transcriptional dysfunction by conditionally replicating adenovirus is not limited by p53-homologues. **Mol Ther**. 2010 May;18(5):936-46.

Bric A, Miething C, Bialucha CU, Scuoppo C, **Zender L**, Krasnitz A, Xuan Z, Zuber J, Wigler M, Hicks J, McCombie RW, Hemann MT, Hannon GJ, Powers S, Lowe SW. Functional identification of tumor-suppressor genes through an in vivo RNA interference screen in a mouse lymphoma model. **Cancer Cell**. 2009 Oct 6;16(4):324-35.

Liu LX, Lee NP, Chan VW, Xue W, **Zender L**, Zhang C, Mao M, Dai H, Wang XL, Xu MZ, Lee TK, Ng IO, Chen Y, Kung HF, Lowe SW, Poon RT, Wang JH, Luk JM. Targeting

cadherin-17 inactivates Wnt signaling and inhibits tumor growth in liver carcinoma. **Hepatology**. 2009 Nov;50(5):1453-63. Erratum in: *Hepatology*. 2010 Jan;51(1):358.

Xu MZ, Yao TJ, Lee NP, Ng IO, Chan YT, **Zender L**, Lowe SW, Poon RT, Luk JM. Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma. **Cancer**. 2009 Oct 1;115(19):4576-85.

Gürlevik E, Woller N, Schache P, Malek NP, Wirth TC, **Zender L**, Manns MP, Kubicka S, Kühnel F. p53-dependent antiviral RNA-interference facilitates tumor-selective viral replication. **Nucleic Acids Res**. 2009 Jul;37(12):e84.

Schache P, Gürlevik E, Strüver N, Woller N, Malek N, **Zender L**, Manns M, Wirth T, Kühnel F, Kubicka S. VSV virotherapy improves chemotherapy by triggering apoptosis due to proteasomal degradation of Mcl-1. **Gene Ther**. 2009 Jul;16(7):849-61.

Ma O, Cai WW, **Zender L**, Dayaram T, Shen J, Herron AJ, Lowe SW, Man TK, Lau CC, Donehower LA. MMP13, Birc2 (cIAP1), and Birc3 (cIAP2), amplified on chromosome 9, collaborate with p53 deficiency in mouse osteosarcoma progression. **Cancer Res**. 2009 Mar 15;69(6):2559-67.

Laska MJ, Lowe SW, **Zender L**, Hearn S, Vogel U, Jensen UB, Bric A, Nexø BA. Enforced expression of PPP1R13L increases tumorigenesis and invasion through p53-dependent and p53-independent mechanisms. **Mol Carcinog**. 2009 Sep;48(9):832-42.

Zender L, Xue W, Zuber J, Semighini CP, Krasnitz A, Ma B, Zender P, Kubicka S, Luk JM, Schirmacher P, McCombie WR, Wigler M, Hicks J, Hannon GJ, Powers S, Lowe SW. An oncogenomics-based in vivo RNAi screen identifies tumor suppressors in liver cancer. **Cell**. 2008 Nov 28;135(5):852-64.

Gyrd-Hansen M, Darding M, Miasari M, Santoro MM, **Zender L**, Xue W, Tenev T, da Fonseca PC, Zvelebil M, Bujnicki JM, Lowe S, Silke J, Meier P. IAPs contain an evolutionarily conserved ubiquitin-binding domain that regulates NF-kappaB as well as cell survival and oncogenesis. **Nat Cell Biol**. 2008 Nov;10(11):1309-17.

Krizhanovsky V, Yon M, Dickins RA, Hearn S, Simon J, Miething C, Yee H, **Zender L**, Lowe SW. Senescence of activated stellate cells limits liver fibrosis. **Cell**. 2008 Aug 22;134(4):657-67.

Burgess DJ, Doles J, **Zender L**, Xue W, Ma B, McCombie WR, Hannon GJ, Lowe SW, Hemann MT. Topoisomerase levels determine chemotherapy response in vitro and in vivo. **Proc Natl Acad Sci U S A**. 2008 Jul 1;105(26):9053-8.

Xue W, Krasnitz A, Lucito R, Sordella R, Vanaelst L, Cordon-Cardo C, Singer S, Kuehnel F, Wigler M, Powers S, **Zender L**, Lowe SW. DLC1 is a chromosome 8p tumor suppressor whose loss promotes hepatocellular carcinoma. **Genes Dev**. 2008 Jun 1;22(11):1439-44.

Dickins RA, McJunkin K, Hernando E, Premssirut PK, Krizhanovsky V, Burgess DJ, Kim SY, Cordon-Cardo C, **Zender L**, Hannon GJ, Lowe SW. Tissue-specific and reversible RNA interference in transgenic mice. **Nat Genet**. 2007 Jul;39(7):914-21.

He L, He X, Lim LP, de Stanchina E, Xuan Z, Liang Y, Xue W, **Zender L**, Magnus J, Ridzon D, Jackson AL, Linsley PS, Chen C, Lowe SW, Cleary MA, Hannon GJ. A microRNA component of the p53 tumour suppressor network. **Nature**. 2007 Jun 28;447(7148):1130-4.

Kirchhoff TD, Bleck JS, Dettmer A, Chavan A, Rosenthal H, Merkesdal S, Frericks B, **Zender L**, Malek NP, Greten TF, Kubicka S, Manns MP, Galanski M. Transarterial chemoembolization using degradable starch microspheres and iodized oil in the treatment of advanced hepatocellular carcinoma: evaluation of tumor response, toxicity, and survival. **Hepatobiliary Pancreat Dis Int**. 2007 Jun;6(3):259-66.

Xue W*, **Zender L***, Miething C, Dickins RA, Hernando E, Krizhanovsky V, Cordon-Cardo C, Lowe SW. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. **Nature**. 2007 Feb 8;445(7128):656-60 (*equal contribution).

Wendel HG, Malina A, Zhao Z, **Zender L**, Kogan SC, Cordon-Cardo C, Pelletier J, Lowe SW. Determinants of sensitivity and resistance to rapamycin-chemotherapy drug combinations in vivo. **Cancer Res**. 2006 Aug 1;66(15):7639-46.

Zender L, Xue W, Cordón-Cardo C, Hannon GJ, Lucito R, Powers S, Flemming P, Spector MS, Lowe SW. Generation and analysis of genetically defined liver carcinomas derived from bipotential liver progenitors. **Cold Spring Harb Symp Quant Biol**. 2005;70:251-61.

Lakshmi B, Hall IM, Egan C, Alexander J, Leotta A, Healy J, **Zender L**, Spector MS, Xue W, Lowe SW, Wigler M, Lucito R. Mouse genomic representational oligonucleotide microarray analysis: detection of copy number variations in normal and tumor specimens. **Proc Natl Acad Sci U S A**. 2006 Jul 25;103(30):11234-9.

Zender L, Spector MS, Xue W, Flemming P, Cordon-Cardo C, Silke J, Fan ST, Luk JM, Wigler M, Hannon GJ, Mu D, Lucito R, Powers S, Lowe SW. Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. **Cell**. 2006 Jun 30;125(7):1253-67.

Dettmer A, Kirchhoff TD, Gebel M, **Zender L**, Malek NP, Panning B, Chavan A, Rosenthal H, Kubicka S, Krusche S, Merkesdal S, Galanski M, Manns MP, Bleck JS. Combination of repeated single-session percutaneous ethanol injection and transarterial chemoembolisation compared to repeated single-session percutaneous ethanol injection in patients with non-resectable hepatocellular carcinoma. **World J Gastroenterol**. 2006 Jun 21;12(23):3707-15.

Wuestefeld T, Klein C, Streetz KL, Beraza N, Schölmerich J, Burgart LJ, **Zender L**, Kubicka S, Baskin-Bey E, Gores GJ, Manns MP, Trautwein C. Lack of gp130 expression results in more bacterial infection and higher mortality during chronic cholestasis in mice. **Hepatology**. 2005 Nov;42(5):1082-90. Erratum in: *Hepatology*. 2005 Dec;42(6):1471. Baskin-Bey, Edwina [added].

Mundt B, Wirth T, **Zender L**, Waltemathe M, Trautwein C, Manns MP, Kühnel F, Kubicka S. Tumour necrosis factor related apoptosis inducing ligand (TRAIL) induces hepatic steatosis in viral hepatitis and after alcohol intake. **Gut**. 2005 Nov;54(11):1590-6.

Wirth T, Kühnel F, Fleischmann-Mundt B, Woller N, Djojosebroto M, Rudolph KL, Manns M, **Zender L**, Kubicka S. Telomerase-dependent virotherapy overcomes resistance of

hepatocellular carcinomas against chemotherapy and tumor necrosis factor-related apoptosis-inducing ligand by elimination of Mcl-1. **Cancer Res.** 2005 Aug 15;65(16):7393-402.

Kirchhoff T, **Zender L**, Merkesdal S, Frericks B, Malek N, Bleck J, Kubicka S, Baus S, Chavan A, Manns MP, Galanski M. Initial experience from a combination of systemic and regional chemotherapy in the treatment of patients with nonresectable cholangiocellular carcinoma in the liver. **World J Gastroenterol.** 2005 Feb 28;11(8):1091-5.

Zender L, Hütker S, Mundt B, Waltemathe M, Klein C, Trautwein C, Malek NP, Manns MP, Kühnel F, Kubicka S. NFkappaB-mediated upregulation of bcl-xl restrains TRAIL-mediated apoptosis in murine viral hepatitis. **Hepatology.** 2005 Feb;41(2):280-8.

Kühnel F, Schulte B, Wirth T, Woller N, Schäfers S, **Zender L**, Manns M, Kubicka S. Protein transduction domains fused to virus receptors improve cellular virus uptake and enhance oncolysis by tumor-specific replicating vectors. **J Virol.** 2004 Dec;78(24):13743-54.

Kossatz U, Dietrich N, **Zender L**, Buer J, Manns MP, Malek NP. Skp2-dependent degradation of p27kip1 is essential for cell cycle progression. **Genes Dev.** 2004 Nov 1;18(21):2602-7.

Kühnel F, Fritsch C, Krause S, Mundt B, Wirth T, Paul Y, Malek NP, **Zender L**, Manns MP, Kubicka S. Doxycycline regulation in a single retroviral vector by an autoregulatory loop facilitates controlled gene expression in liver cells. **Nucleic Acids Res.** 2004 Feb 13;32(3):e30.

Kühnel F, **Zender L**, Wirth T, Schulte B, Trautwein C, Manns M, Kubicka S. Tumor-specific adenoviral gene therapy: transcriptional repression of gene expression by utilizing p53-signal transduction pathways. **Cancer Gene Ther.** 2004 Jan;11(1):28-40.

Zender L, Hutker S, Liedtke C, Tillmann HL, Zender S, Mundt B, Waltemathe M, Gosling T, Flemming P, Malek NP, Trautwein C, Manns MP, Kuhnel F, Kubicka S. Caspase 8 small interfering RNA prevents acute liver failure in mice. **Proc Natl Acad Sci U S A.** 2003 Jun 24;100(13):7797-802.

Wirth T, **Zender L**, Schulte B, Mundt B, Plentz R, Rudolph KL, Manns M, Kubicka S, Kühnel F. A telomerase-dependent conditionally replicating adenovirus for selective treatment of cancer. **Cancer Res.** 2003 Jun 15;63(12):3181-8.

Mundt B, Kühnel F, **Zender L**, Paul Y, Tillmann H, Trautwein C, Manns MP, Kubicka S. Involvement of TRAIL and its receptors in viral hepatitis. **FASEB J.** 2003 Jan;17(1):94-6.

Zender L, Köck R, Eckhard M, Frericks B, Gösling T, Gebhardt T, Drobek S, Galanski M, Kühnel F, Manns M, Kubicka S. Gene therapy by intrahepatic and intratumoral trafficking of p53-VP22 induces regression of liver tumors. **Gastroenterology.** 2002 Aug;123(2):608-18.

Wiemann SU, Satyanarayana A, Tsahuridu M, Tillmann HL, **Zender L**, Klempnauer J, Flemming P, Franco S, Blasco MA, Manns MP, Rudolph KL. Hepatocyte telomere shortening and senescence are general markers of human liver cirrhosis. **FASEB J.** 2002 Jul;16(9):935-42.

Zender L, Kühnel F, Köck R, Manns M, Kubicka S. VP22-mediated intercellular transport of p53 in hepatoma cells in vitro and in vivo. **Cancer Gene Ther**. 2002 Jun;9(6):489-96.

Kubicka S, Claas C, Staab S, Kühnel F, **Zender L**, Trautwein C, Wagner S, Rudolph KL, Manns M. p53 mutation pattern and expression of c-erbB2 and c-met in gastric cancer: relation to histological subtypes, Helicobacter pylori infection, and prognosis. **Dig Dis Sci**. 2002 Jan;47(1):114-21.

Niehof M, Kubicka S, **Zender L**, Manns MP, Trautwein C. Autoregulation enables different pathways to control CCAAT/enhancer binding protein beta (C/EBP beta) transcription. **J Mol Biol**. 2001 Jun 15;309(4):855-68.

Tietze MK, Wuestefeld T, Paul Y, **Zender L**, Trautwein C, Manns MP, Kubicka S. IkappaBalpha gene therapy in tumor necrosis factor-alpha- and chemotherapy-mediated apoptosis of hepatocellular carcinomas. **Cancer Gene Ther**. 2000 Oct;7(10):1315-23.

Kühnel F*, **Zender L***, Paul Y, Tietze MK, Trautwein C, Manns M, Kubicka S. NFkappaB mediates apoptosis through transcriptional activation of Fas (CD95) in adenoviral hepatitis. **J Biol Chem**. 2000 Mar 3;275(9):6421-7 (*equal contribution).

Kubicka S, Kühnel F, **Zender L**, Rudolph KL, Plümpe J, Manns M, Trautwein C. p53 represses CAAT enhancer-binding protein (C/EBP)-dependent transcription of the albumin gene. A molecular mechanism involved in viral liver infection with implications for hepatocarcinogenesis. **J Biol Chem**. 1999 Nov 5;274(45):32137-44. IF: 5,33

Reviews and book articles:

Zender L. Cancer: interference identifies immune modulators. **Nature**. 2014 Feb 6;506(7486):39-40. doi: 10.1038/nature13050. Epub 2014 Jan 29. PubMed PMID: 24476819.

Wieder T, Braumüller H, Brenner E, Zender L, Röcken M. Changing T cell enigma: Cancer killing or cancer control? *Cell Cycle*. 2013 Aug 26;12(19). [Epub ahead of print] PubMed PMID: 24013429.

Yeysa T, Kang TW, **Zender L**. Immune surveillance of pre-cancerous senescent hepatocytes limits hepatocellular carcinoma development. *Oncoimmunology*. 2012 May 1;1(3):398-399.

Hoenicke L, **Zender L**. Immune surveillance of senescent cells--biological significance in cancer- and non-cancer pathologies. *Carcinogenesis*. 2012 Jun;33(6):1123-6. Epub 2012 Apr 2.

Zender, L, Lowe SW, Mosaic Cancer mouse models and Functional Oncogenomics in Hepatocellular Carcinoma, In: **Genetics of Liver Neoplasia**, Springer.

Wuestefeld T, **Zender L**. DLC1 and Liver Cancer: The Akt Connection. **Gastroenterology**. 2010 Aug 24.

Zender L, Villanueva A, Tovar V, Sia D, Chiang DY, Llovet JM. Cancer gene discovery in hepatocellular carcinoma. **J Hepatol**. 2010 Jun;52(6):921-9.

Zender L, Rudolph KL. Keeping your senescent cells under control. **Aging** (Albany NY). 2009 May 6;1(5):438-41.

Krizhanovsky V, Xue W, **Zender L**, Yon M, Hernando E, Lowe SW. Implications of cellular senescence in tissue damage response, tumor suppression, and stem cell biology. **Cold Spring Harb Symp Quant Biol**. 2008;73:513-22.

Zender L, Kubicka S. Molecular pathogenesis and targeted therapy of hepatocellular carcinoma. **Onkologie**. 2008 Oct;31(10):550-5.

Zender L, Kubicka S. Androgen receptor and hepatocarcinogenesis: what do we learn from HCC mouse models? **Gastroenterology**. 2008 Sep;135(3):738-40.

Zender L, Lowe SW. Integrative oncogenomic approaches for accelerated cancer-gene discovery. **Curr Opin Oncol**. 2008 Jan;20(1):72-6.

Zender L, Zuber J, Lowe SW. Snapshot: genetic mouse models of cancer. **Cell**. 2007 May 18;129(4):838.

Zender L, Kubicka S. Suppression of apoptosis in the liver by systemic and local delivery of small-interfering RNAs. **Methods Mol Biol**. 2007;361:217-26.

Zender L, Kubicka S. SiRNA based strategies for inhibition of apoptotic pathways in vivo--analytical and therapeutic implications. **Apoptosis**. 2004 Jan;9(1):51-4.

Kubicka S, Malek NP, **Zender L**. [Hepatocellular carcinoma--a chemosensitive tumor?]. **Dtsch Med Wochenschr**. 2003 Jun 13;128 Suppl 2:S115-7.

Zender L, Manns MP, Kubicka S. RNA Interference studies in acute liver failure. In: "**RNA Interference Technology: From Basic Biology to drug development**". Cambridge University Press, 28; 396-406. Cambridge UK. 2005.